BACKGROUND Use of antipsychotics to treat behavioural symptoms of dementia has been associated with increased risks of mortality and stroke. Little is known about individual patient characteristics that might be associated with bad or good outcomes. AIMS We examined the risperidone clinical trial data to look for individual patient characteristics associated with these adverse outcomes. MET...

The purpose of this study was to investigate the change in plasma protein expression in first episode schizophrenia after an 8-week treatment with risperidone, and to explore potential biomarkers for metabolic side effects associated with risperidone treatment. Eighty first-episode schizophrenia patientswere enrolled in the study. Fifteen of the 80 patients were randomly selected to undergo pro...

BACKGROUND As schizophrenia patients are typically suspicious of, or are hostile to changes they may be reluctant to accept generic substitution, possibly affecting compliance. This may counteract drug costs savings due to less symptom control and increased hospitalization risk. Although compliance losses following generic substitution have not been quantified so far, one can estimate the possi...

To the Editor: Within the past 3 years, the US Food and Drug Administration (FDA) approved risperidone for the treatment of irritability (which includes behaviors such as aggression, selfinjury, and temper tantrums) associated with autism in children and adolescents 5 to 16 years of age. This approval was the first of its kind and was given in part on the basis of the results of clinical trials...

Paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (PER), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009. However, at the same time, its comparatively high cost gave rise to concerns about the cost-effective...

Tardive dyskinesia (TD) is a neuroleptic-induced movement disorder, and is recognised as a late adverse effect of neuroleptic drugs. We report a case of TD associated with risperidone, a new “atypical” antipsychotic drug. Risperidone has a high affinity for D2 dopamine and 5-HT2 receptors [8 1. Thus, it produces less extrapyramidal side effects (EPS) than classical neuroleptics. Also, risperido...

Follow-up data on 97 of the 101 patients at a university-based psychiatric hospital for whom risperidone had been prescribed between February 1994, when the medication was introduced, and October 1996 were reviewed an average of 102 weeks after the start of the medication. Only 28.9 percent of the patients were still on risperidone at follow-up. Patients who were maintained on risperidone were ...

Risperidone has been found to be useful in the treatment of acute bipolar disorders. This is a case report where risperidone mono therapy has been found to be effective in prophylaxis of bipolar affective disorder. The pharmacological and clinical implications of risperidone in the management of BPAD are discussed.

A simple, rapid and sensitive high-performance liquid chromatographic (HPLC) method for the determination of risperidone in human plasma was developed. An HPLC system based on a Nucleosil C8 column (150?4 mm) and a UV detector (?= 280 nm) were used. A mixture of sodium dihydrogen phosphate buffer-acetonitrile (55:45, v/v) adjusted to pH 6.0 at a flow rate of 1.5 ml min-1 was used as mobile phas...

In the present study was examined the effect of treatment with olanzapine or risperidone, given separately or in combination with fluoxetine, in the elevated plus-maze test (an animal model of anxiety) in male Wistar rats. The obtained results showed that treatment with olanzapine (1 mg/kg), risperidone (0.1 and 0.3 mg/kg) or fluoxetine (5 and 10 mg/kg) induced an anxiolytic-like effect in the ...